日本語 中文
Contact

Search results

Showing 20 of 457 results for term: 凪光 退役了吗

  • Supplying delivery systems to help prevent cardiovascular disease

    Nucleic acid-based therapies are the next big blockbuster drug class opening up exciting applications such as gene editing, where a patient’s genetic material can be modified to correct a disorder.

  • Supporting the next generation of therapeutic vaccines

    Vaccine adjuvants are used to enhance immune response to an antigen, improving the overall efficacy of the vaccine and increasing protection against the target disease.

  • Bringing anti-ageing benefits to make-up

    Developed through one of our Smart Partnerships, Majestem® Drypure™ from our beauty actives business, Sederma, brings anti-ageing and environmental protection benefits to make-up.

  • Sustainability-linked revolving credit facility

    In 2019, we became one of the UK’s first large public companies to include a sustainability metric in a revolving credit facility (RCF), with targets in the seven-year agreement aligned with our 2030 Commitment to become Climate Positive.

  • Collaboration to develop alternative vaccine adjuvants

    In 2021 we established a strategic collaboration with the Danish Government’s life science research institute, Statens Serum Institute (SSI).

  • Investors

    Investor information including financial reporting and events.

  • Investor seminar on our Life Sciences sector

    7 October 2019: Senior members of our management team provided a comprehensive overview of the Life Sciences sector, with a particular focus on our Health Care business.

  • Site visit to Sederma Beauty Actives business in France

    17-18 March 2016: Croda International plc hosted a Capital Markets Event for analysts and investors at its Sederma facility near Versailles, France.

  • Analyst consensus

    Consensus collated from estimates submitted by side-sell analysts on Croda International Plc.

  • Acquisitions

    Commercialising and increasing our access to new ideas and technologies.

  • Regulatory news

    Our most recent announcements to the stock exchange.

  • About us

    We are the name behind high performance ingredients and technologies in some of the most successful brands in the world.

  • EMEA

    Our global headquarters are based in Yorkshire in the UK. We also have a number of offices and manufacturing sites spread across the region.

  • USA

    Croda Inc is the North American headquarters for Croda, with over 800 employees, working in a variety of roles in manufacturing, sales, marketing and research and development.

  • North America

    Croda Inc is the North American headquarters for Croda, we have four manufacturing sites, four innovation centres and four sales hubs in the region.

  • UK Pensions

    Explore information on Croda UK pensions, including state pensions, workplace schemes, death benefits and retirement.

  • People Positive

    By 2030, we will be People Positive.

  • Life Sciences sustainability review

    Sustainability is embedded in our business strategy, shaping innovation and meeting customer expectations. In Life Sciences, it drives impact, performance and long-term value.

  • Chief Executive sustainability statement

    “By thinking boldly, acting with purpose, and living our values every day, we are bringing Smart science to improve lives™ to life and working hard to achieve our commitment to be the most sustainable supplier of innovative ingredients by 2030, delivering solutions to tackle some of the world’s biggest challenges”

  • Media coverage Page Summary Title

    Media coverage Page Summary Description